For years, prescription drug prices in the United States have spiraled upwards, seemingly immune to the forces of market competition. But with Medicare finally authorized to negotiate drug prices, a new era is dawning. And in this era, the cozy relationship between Big Pharma and direct-to-consumer (DTC) advertising is about to face intense scrutiny.